Skip to main content
SpringerLink
Log in

Posaconazole cost effective for IFD prevention in Spain

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. The study was funded by MSD Sharp & Dohme.

Reference

  • Grau S, et al. Cost-effectiveness of posaconazole tablets versus fluconazole as prophylaxis for invasive fungal diseases in patients with graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. European Journal of Health Economics : 31 May 2017. Available from: URL: http://dx.doi.org/10.1007/s10198-017-0907-5

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Posaconazole cost effective for IFD prevention in Spain. PharmacoEcon Outcomes News 780, 28 (2017). https://doi.org/10.1007/s40274-017-4080-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-017-4080-y

Search

Navigation